CVAR - ETF AI Analysis
Top Page
Cultivar ETF (CVAR)
Rating:59Neutral
Price Target:―
Positive Factors
Broad Sector Diversification
The ETF spreads its investments across many different sectors, which can help reduce the impact if any one industry runs into trouble.
Multiple Strong Top Holdings
Several of the largest positions, particularly in health care and utilities, have shown strong year-to-date performance, supporting the fund’s overall results.
Positive Recent Performance
The fund has delivered positive returns so far this year, with especially strong gains in the most recent month.
Negative Factors
High Expense Ratio
The ETF charges a relatively high fee, which can eat into long-term returns compared with lower-cost alternatives.
U.S.-Heavy Geographic Exposure
With most assets invested in U.S. companies, the fund offers limited diversification across other global markets.
Some Weak Top Holdings
A few of the largest positions have shown weak year-to-date performance, which could drag on the fund if those stocks do not recover.
CVAR vs. SPDR S&P 500 ETF (SPY)
AUM45.86M
RegionNorth America
Expense Ratio0.87%
Beta0.57
IssuerCultivar
Inception DateDec 21, 2021
Dividend Yield1.39%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume1,435
30 Day Avg. Volume2,360
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
34.01Price Target Upside― Downside
Rating ConsensusHold
Number of Analyst Covering88
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
CVAR Summary
CVAR, the Cultivar ETF, is a value-focused fund that looks for U.S. companies across the whole stock market that appear undervalued but have solid business fundamentals. It doesn’t track a specific index, but follows a value investing theme, holding a mix of large, mid, and small companies in sectors like health care, technology, and consumer goods. Well-known names in the fund include Kimberly-Clark and Dollar General. Someone might invest in CVAR to diversify their portfolio while aiming for long-term growth from overlooked stocks. A key risk is that value stocks can stay out of favor for long periods, so the price can go up and down with the market.
How much will it cost me?The Cultivar ETF (CVAR) has an expense ratio of 0.87%, which means you’ll pay $8.70 per year for every $1,000 invested. This expense ratio is higher than average because the fund is actively managed, focusing on identifying undervalued companies with strong fundamentals rather than simply tracking an index.
What would affect this ETF?The Cultivar ETF (CVAR) could benefit from a recovery in the U.S. economy, as value investing strategies often perform well during periods of market stability and growth. Positive trends in sectors like Health Care and Technology, which make up significant portions of the ETF, could also drive returns. However, rising interest rates or economic uncertainty might negatively impact some of its top holdings, such as real estate and energy companies, and broader market volatility could challenge its value-focused approach.
CVAR Top 10 Holdings
CVAR’s story is driven by a mix of rising health care and tech value names, with a few trouble spots tugging at returns. Paycom and Illumina have been clear bright spots, climbing steadily and giving the fund a growthy kick despite its value tilt. Veeva and Humana are also helping, adding steady, if less dramatic, support. On the other side, Intuit looks like it’s losing steam this year, while Core Laboratories has been dragging. Overall, the ETF is U.S.-focused and leans heavily into health care and technology as its main engines.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Marketaxess Holdings | 2.48% | $1.13M | $5.74B | -11.82% | 68 Neutral | |
| Healthcare Services | 2.41% | $1.10M | $1.51B | 37.20% | 72 Outperform | |
| Core Laboratories | 2.32% | $1.06M | $573.56M | 0.97% | 72 Outperform | |
| Paycom | 2.08% | $947.44K | $9.69B | -1.67% | 76 Outperform | |
| Alexandria Equities | 2.06% | $936.17K | $8.91B | -39.78% | 47 Neutral | |
| Kimberly Clark | 2.01% | $912.89K | $32.64B | -23.31% | 63 Neutral | |
| Veeva Systems | 1.95% | $885.08K | $42.48B | -5.08% | 66 Neutral | |
| Humana | 1.88% | $854.02K | $49.21B | 48.24% | 69 Neutral | |
| Illumina | 1.83% | $831.17K | $31.17B | 117.04% | 71 Outperform | |
| Dollar General | 1.75% | $797.31K | $27.48B | 19.33% | 73 Outperform |
CVAR Technical Analysis
Positive
―
Price Trends
30.57
Positive
29.61
Positive
29.28
Positive
Market Momentum
0.10
Positive
49.16
Neutral
21.39
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For CVAR, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 31.49, equal to the 50-day MA of 30.57, and equal to the 200-day MA of 29.28, indicating a neutral trend. The MACD of 0.10 indicates Positive momentum. The RSI at 49.16 is Neutral, neither overbought nor oversold. The STOCH value of 21.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CVAR.
CVAR Peer Comparison
Comparison Results
Performance Comparison
CVAR
Cultivar ETF
31.08
3.83
14.06%
BAMD
Brookstone Dividend Stock ETF
―
―
―
VUSV
Vanguard Wellington U.S. Value Active ETF
―
―
―
SASS
M.D. Sass Concentrated Value ETF
―
―
―
GVLE
Goldman Sachs Value Opportunities ETF
―
―
―
USFE
First Eagle US Equity ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents